Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Review

Multicenter Study

Clinical Trial

Research Support, N.I.H., Extramural

Clinical Trial, Phase III

Comparative Study

Research Support, U.S. Gov't, P.H.S.

Observational Study

Publication Year

From

Quick links

Individual year

2021

2020

2018

2015

2012

2011

2009

2008

2007

2005

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Group II Phospholipases A2""[mesh_terms]

14 Results

Searching titles within these results

PLA2 mediated arachidonate free radicals: PLA2 inhibition and neutralization of free radicals by anti-oxidants--a new role as anti-inflammatory molecule.

B L Nanda, A Nataraju, R Rajesh, K S Rangappa, M A Shekar, B S Vishwanath

Current topics in medicinal chemistry 2007;7(8):765-77

Full Text

Abstract

The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

Dimitar Divchev, Bernhard Schieffer

Vascular health and risk management 2008;4(3):597-604

Free Full Text

Abstract

Can Inhibitors of Snake Venom Phospholipases A₂ Lead to New Insights into Anti-Inflammatory Therapy in Humans? A Theoretical Study.

Thaís A Sales, Silvana Marcussi, Elaine F F da Cunha, Kamil Kuca, Teodorico C Ramalho

Toxins 2018;9(11):341

Free Full Text

Abstract

RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.

Flor Torres-Juarez, Lousseine Touqui, Juan Leon-Contreras, Cesar Rivas-Santiago, Jose A Enciso-Moreno, Rogelio Hernández-Pando, Bruno Rivas-Santiago

Pathogens and disease 2018;76(2):

Full Text

Abstract

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.

Bernhardt G Zeiher, Jay Steingrub, Pierre-Francois Laterre, Alex Dmitrienko, Yonetaka Fukiishi, Edward Abraham

Critical care medicine 2005;33(8):1741-8

Full Text

Abstract

Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality.

Justin M Snider, Jeehyun Karen You, Xia Wang, Ashley J Snider, Brian Hallmark, Manja M Zec, Michael C Seeds, Susan Sergeant, Laurel Johnstone, Qiuming Wang, Ryan Sprissler, Tara F Carr, Karen Lutrick, Sairam Parthasarathy, Christian Bime, Hao Helen Zhang, Chiara Luberto, Richard R Kew, Yusuf A Hannun, Stefano Guerra, Charles E McCall, Guang Yao, Maurizio Del Poeta, Floyd H Chilton

The Journal of clinical investigation 2021;131(19):e149236

Free Full Text

Abstract

The application of rational design on phospholipase A(2) inhibitors.

V D Mouchlis, E Barbayianni, T M Mavromoustakos, G Kokotos

Current medicinal chemistry 2011;18(17):2566-82

Full Text

Abstract

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

Colin Hislop, Robert S Rosenson, Heather Fraser, Michael A Goulder

Cardiovascular drugs and therapy 2012;25(6):539-44

Full Text

Abstract

Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.

Dimitar Divchev, Christina Grothusen, Maren Luchtefeld, Martin Thoenes, Frederick Onono, Rainer Koch, Helmut Drexler, Bernhard Schieffer

European heart journal 2009;29(16):1956-65

Full Text

Abstract

Group IIA Secretory Phospholipase A, Vascular Inflammation, and Incident Cardiovascular Disease.

Akintunde O Akinkuolie, Patrick R Lawler, Audrey Y Chu, Michael Caulfield, Jianying Mu, Bo Ding, Fredrik Nyberg, Robert J Glynn, Paul M Ridker, Eva Hurt-Camejo, Daniel I Chasman, Samia Mora

Arteriosclerosis, thrombosis, and vascular biology 2020;39(6):1182-1190

Free Full Text

Abstract

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

Iain B McInnes, Liz Thompson, Jon T Giles, Joan M Bathon, Jane E Salmon, Andre D Beaulieu, Christine E Codding, Timothy H Carlson, Christian Delles, Janet S Lee, Naveed Sattar

Annals of the rheumatic diseases 2015;74(4):694-702

Free Full Text

Abstract

Expression of Ca(2+)-independent and Ca(2+)-dependent phospholipases A(2) and cyclooxygenases in human melanocytes and malignant melanoma cell lines.

Mariagrazia Rita Scuderi, Carmelina Daniela Anfuso, Gabriella Lupo, Carla Motta, Loriana Romeo, Liliana Guerra, Alessandro Cappellani, Nicola Ragusa, Giuseppina Cantarella, Mario Alberghina

Biochimica et biophysica acta 2008;1781(10):635-42

Full Text

Abstract

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Edward Abraham, Chris Naum, Venkata Bandi, Daniel Gervich, Stephen F Lowry, Richard Wunderink, Roland M Schein, William Macias, Simona Skerjanec, Alex Dmitrienko, Nagy Farid, S Thomas Forgue, Frank Jiang

Critical care medicine 2003;31(3):718-28

Full Text

Abstract

Structure, function and interfacial allosterism in phospholipase A2: insight from the anion-assisted dimer.

Brian J Bahnson

Archives of biochemistry and biophysics 2005;433(1):96-106

Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Group II Phospholipases A2""[mesh_terms]

PLA2 mediated arachidonate free radicals: PLA2 inhibition and neutralization of free radicals by anti-oxidants--a new role as anti-inflammatory molecule.

The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

Can Inhibitors of Snake Venom Phospholipases A₂ Lead to New Insights into Anti-Inflammatory Therapy in Humans? A Theoretical Study.

RNase 7 but not psoriasin nor sPLA2-IIA associates with Mycobacterium tuberculosis during airway epithelial cell infection.

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.

Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality.

The application of rational design on phospholipase A(2) inhibitors.

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.

Group IIA Secretory Phospholipase A, Vascular Inflammation, and Incident Cardiovascular Disease.

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

Expression of Ca(2+)-independent and Ca(2+)-dependent phospholipases A(2) and cyclooxygenases in human melanocytes and malignant melanoma cell lines.

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Structure, function and interfacial allosterism in phospholipase A2: insight from the anion-assisted dimer.

Results for
""Group II Phospholipases A2""[mesh_terms]